Journal of Guangxi Normal University(Natural Science Edition) ›› 2025, Vol. 43 ›› Issue (6): 162-173.doi: 10.16088/j.issn.1001-6600.2024121301

• Ecology and Environmental Science Research • Previous Articles     Next Articles

Anti-Tumor Activity of Oxalamide Derivative Z21 in Human Hepatoma Cell Line Hep G2

XIE Wenbin1,2, YU Yuhui1,2, YU Haishuang1,2, WU Huixian1,2, JIN Junfei1,2, CHEN Zhenfeng3, LU Xing1,2*   

  1. 1. Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair (Affiliated Hospital of Guilin Medical University), Guilin Guangxi 541001, China;
    2. Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases (Affiliated Hospital of Guilin Medical University), Guilin Guangxi 541001, China;
    3. State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University), Guilin Guangxi 541004, China
  • Received:2024-12-13 Revised:2025-01-18 Published:2025-11-19

PDF (PC)

1

Abstract: In this study, the activity and mechanism of a novel anti-tumor compound oxalamide derivative Z21 were studied. Activity screening showed that Z21 could effectively inhibit the growth of various tumor cell lines, especially human hepatoma cell line Hep G2 cells. With Hep G2 cells as experimental subjects, we observed cell morphology by microscope, detected cell viability by MTT assay and ATP assay, detected cell proliferation capacity by EdU incorporation assay and clonal formation assay, detected cell cycle by PI staining, detected cell apoptosis by Annexin V/PI staining, and detected the expressions of apoptosis-related proteins by Western blot. Mechanism studies showed that Z21 suppressed the proliferation of Hep G2 cells in a dose-dependent manner, reduced the expression of Bcl-2, promoted the expression of Bax and significantly induced cell apoptosis by caspase-dependent apoptosis pathway, but no significant cell cycle arrest was observed. These results indicate that Z21 contains great anti-tumor activity, and its ability to suppresses the proliferation of Hep G2 cells may be related to inducing cell apoptosis.

Key words: oxalamide derivative, hepatoma, anti-tumor, Hep G2, cell apoptosis

CLC Number:  R735.7
[1] 夏永祥, 张峰, 李相成, 等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志, 2021(1): 6-17.
[2] 杨宁, 沈锋. 综合治疗时代肝癌外科手术治疗地位与时机变迁[J]. 中国实用外科杂志, 2024, 44(9): 1010-1015. DOI: 10.19538/j.cjps.issn1005-2208.2024.09.09.
[3] 霍群, 刘杰, 陈莉, 等. 血清AFP临界值判断对肝癌诊断的影响[J]. 广西师范大学学报(自然科学版), 2014, 32(3): 121-124. DOI: 10.16088/j.issn.1001-6600.2014.03.044.
[4] YANG C, ZHANG H L, ZHANG L M, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nature Reviews Gastroenterology & Hepatology, 2023, 20(4): 203-222. DOI: 10.1038/s41575-022-00704-9.
[5] WANG Y, DENG B C. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Reviews, 2023, 42(3): 629-652. DOI: 10.1007/s10555-023-10084-4.
[6] 林万华, 赵林, 刘晓灿, 等. HDGF基因在肝癌和癌旁组织中表达情况的检测[J]. 广西师范大学学报(自然科学版), 2014, 32(1): 118-122. DOI: 10.16088/j.issn.1001-6600.2014.01.024.
[7] 罗茜茜, 陈佳梅, 石薇, 等. 晚期原发性肝癌靶向及免疫治疗的研究进展[J]. 山东医药, 2023, 63(1): 92-96.
[8] HUANG L Z, XU R, LI W R, et al. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy[J]. Acta Biomaterialia, 2023, 162: 98-109. DOI: 10.1016/j.actbio.2023.03.014.
[9] ABOU-ALFA G K, MEYER T, CHENG A L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. New England Journal of Medicine, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
[10] THOMAS M B, GARRETT-MAYER E, ANIS M, et al. A randomized phase Ⅱ open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma[J]. Oncology, 2018, 94(6): 329-339. DOI: 10.1159/000485384.
[11] SUGIMOTO R, SATOH T, UEDA A, et al. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: a multicenter prospective observational study[J]. Medicine, 2022, 101(40): e30871. DOI: 10.1097/MD.0000000000030871.
[12] FINN R S, QIN S K, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. New England Journal of Medicine, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[13] YAO C Y, WU S L, KONG J, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies[J]. Cancer Biology & Medicine, 2023, 20(1): 25-43. DOI: 10.20892/j.issn.2095-3941.2022.0449.
[14] TAHMASVAND R, DEHGHANI S, KOOSHAFAR Z, et al. In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer[J]. Naunyn-Schmiedeberg’s Archieves of Pharmacology, 2024, 397(7): 5119-5129. DOI: 10.1007/s00210-023-02931-6.
[15] MOTATI D R, UREDI D, WATKINS E B. The discovery and development of oxalamide and pyrrole small molecule inhibitors of gp120 and HIV entry: a review[J]. Current Topics in Medicinal Chemistry, 2019, 19(18): 1650-1675. DOI: 10.2174/1568026619666190717163959.
[16] FU H L, ZHENG K, ZHANG M J, et al. Synthesis and structure of new tetracopper (Ⅱ) complexes with N-benzoate-N′-[3-(diethylamino)propyl] oxamide as a bridging ligand: the influence of hydrophobicity on enhanced DNA/BSA-binding and anticancer activity[J]. Journal of Photochemistry and Photobiology B: Biology, 2016, 161: 80-90. DOI: 10.1016/j.jphotobiol.2016.04.032.
[17] ZHENG K, LIU F, LI Y T, et al. Synthesis and structure elucidation of new μ-oxamido-bridged dicopper (Ⅱ) complexes showing in vitro anticancer activity: evaluation of DNA/protein-binding properties by experiment and molecular docking[J]. Journal of Inorganic Biochemistry, 2016, 156: 75-88. DOI: 10.1016/j.jinorgbio.2015.12.023.
[18] WEINBERG E M, CURRY M P, FRENETTE C T, et al. Multicenter, double-blind, randomized trial of emricasan in hepatitis C-treated liver transplant recipients with residual fibrosis or cirrhosis[J]. Liver Transplantation, 2021, 27(4): 568-579. DOI: 10.1002/lt.25934.
[19] FRENETTE C, KAYALI Z, MENA E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis[J]. Journal of Hepatology, 2021, 74(2): 274-282. DOI: 10.1016/j.jhep.2020.09.029.
[20] NASSAUER L, SCHOTT J W, HARRE J, et al. The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells[J]. Journal of Molecular Medicine, 2024, 102(9): 1163-1174. DOI: 10.1007/s00109-024-02472-2.
[21] 霍红月, 李仲庆, 覃其品, 等. 邻香草醛缩胡椒乙胺席夫碱锌(Ⅱ)配合物的研究[J]. 广西师范大学学报(自然科学版), 2014, 32(3): 65-73. DOI: 10.16088/j.issn.1001-6600.2014.03.036.
[22] ATLĞŞEKEROĞLU Z, ŞEKEROĞLU V, IŞK S, et al. Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells[J]. Clinics and Research in Hepatology and Gastroenterology, 2021, 45(6): 101632. DOI: 10.1016/j.clinre.2021.101632.
[23] ANGELOZZI M, DE CHARLEROY C R, LEFEBVRE V. EdU-based assay of cell proliferation and stem cell quiescence in skeletal tissue sections[J]. Methods in Molecular Biology, 2021, 2230: 357-365. DOI: 10.1007/978-1-0716-1028-2_21.
[24] KASHYAP A, UMAR S M, DEV J R A, et al. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis[J]. Journal of Cellular Biochemistry, 2023, 124(9): 1259-1272. DOI: 10.1002/jcb.30443.
[25] JAMASBI E, HAMELIAN M, HOSSAIN M A, et al. The cell cycle, cancer development and therapy[J]. Molecular Biology Reports, 2022, 49(11): 10875-10883. DOI: 10.1007/s11033-022-07788-1.
[26] NEWTON K, STRASSER A, KAYAGAKI N, et al. Cell death[J]. Cell, 2024, 187(2): 235-256. DOI: 10.1016/j.cell.2023.11.044.
[27] SAHOO G, SAMAL D, KHANDAYATARAY P, et al. A review on caspases: key regulators of biological activities and apoptosis[J]. Molecular Neurobiology, 2023, 60(10): 5805-5837. DOI: 10.1007/s12035-023-03433-5.
[28] LADD A D, DUARTE S, SAHIN I, et al. Mechanisms of drug resistance in HCC[J]. Hepatology, 2024, 79(4): 926-940. DOI: 10.1097/HEP.0000000000000237.
[29] 刘慧, 李丽, 刘洋汉, 等. 肿瘤相关巨噬细胞靶向治疗研究进展[J]. 广西师范大学学报(自然科学版), 2022, 40(5): 286-299. DOI: 10.16088/j.issn.1001-6600.2021122303.
[30] 王强, 张治清. 有氧糖酵解在肝癌中的研究进展[J]. 局解手术学杂志, 2024, 33(11): 963-966. DOI: 10.11659/jjssx.08E023056.
[31] GILLANI T B, RAWLING T, MURRAY M. Cytochrome P450-mediated biotransformation of sorafenib and its N-oxide metabolite: implications for cell viability and human toxicity[J]. Chemical Research in Toxicology, 2015, 28(1): 92-102. DOI: 10.1021/tx500373g.
[32] ROY D, SHENG G Y, HERVE S, et al. Interplay between cancer cell cycle and metabolism: challenges, targets and therapeutic opportunities[J]. Biomedicine & Pharmacotherapy, 2017, 89: 288-296. DOI: 10.1016/j.biopha.2017.01.019.
[33] LI Q Z, CHEN Y Y, LIU Q P, et al. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest[J]. Phytomedicine, 2024, 126: 155177. DOI: 10.1016/j.phymed.2023.155177.
[34] ABUSALIYA A, JEONG S H, BHOSALE P B, et al. Mechanistic action of cell cycle arrest and intrinsic apoptosis via inhibiting Akt/mTOR and activation of p38-MAPK signaling pathways in Hep3B liver cancer cells by prunetrin-a flavonoid with therapeutic potential[J]. Nutrients, 2023, 15(15): 3407. DOI: 10.3390/nu15153407.
[35] GAO X, JIANG Y H, XU Q, et al. 4-hydroxyderricin promotes apoptosis and cell cycle arrest through regulating PI3K/AKT/mTOR pathway in hepatocellular cells[J]. Foods, 2021, 10(9): 2036. DOI: 10.3390/foods10092036.
[1] XIE Wenbin, JIN Junfei, CHEN Zhenfeng, LU Xing. Advances of Photoactivated Prodrugs in Anti-Tumor Therapy [J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(5): 16-40.
[2] DU Libo, LI Jinyu, ZHANG Xiao, LI Yonghong, PAN Weidong. Chemical Constituents and Biological Activity from the Bark of Toona ciliata var. pubescens [J]. Journal of Guangxi Normal University(Natural Science Edition), 2022, 40(4): 162-172.
[3] SUN Li, CHU Xiangwu, LIU Chunmei, ZHANG Juzheng, CHENG Keguang. Synthesis and Anti-tumor Activities of Ursolic Acid and Glycyrrhetinic Acid-Uridine Conjugates [J]. Journal of Guangxi Normal University(Natural Science Edition), 2020, 38(1): 87-92.
[4] LIU Guan-yan, CHENG Ke-guang, DENG Sheng-ping, LIU Yan-cheng, CHUXiang-wu, CHEN Jian-hui, MA Lu. Synthesis and Anti-tumor Activity Evaluation of Estradiol Ester Derivatives [J]. Journal of Guangxi Normal University(Natural Science Edition), 2013, 31(1): 62-66.
[5] NIE Yue-kun, PAN Cheng-xue, DAI Zhi-kai, SU Gui-fa. Synthesis and Bioactivities of Benzo[c]phenanthridine Derivatives [J]. Journal of Guangxi Normal University(Natural Science Edition), 2012, 30(1): 60-66.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] LIU Xiaojuan, LIN Lu, HU Yucong, PAN Lei. Research on the Influence of Land Use Types Surrounding Stations on Subway Passenger Satisfaction[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 1 -12 .
[2] HAN Huabin, GAO Bingpeng, CAI Xin, SUN Kai. Fault Diagnosis of Wind Turbine Blade Icing Based on HO-CNN-BiLSTM-Transformer Model[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 13 -28 .
[3] CHEN Jianguo, LIANG Enhua, SONG Xuewei, QIN Zhangrong. Lattice Boltzmann Simulation for the Aqueous Humour Dynamics of the Human Eye Based on 3D Reconstruction of OCT Images[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 29 -41 .
[4] LI Hao, HE Bing. Droplet Rebound Behavior on Grooves Surface[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 42 -53 .
[5] LING Fu, ZHANG Yonggang, WEN Binghai. Study on Curve Boundary Algorithm of Multiphase Lattice Boltzmann Method Based on Interpolation[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 54 -68 .
[6] XIE Sheng, MA Haifei, ZHANG Canlong, WANG Zhiwen, WEI Chunrong. Multi-resolution Feature Grounding for Cross-Modal Person Retrieval[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 69 -79 .
[7] WEI Zishu, CHEN Zhigang, WANG Yanxue, Hasitieer Madetihan. Lightweight Bearing Defect Detection Algorithm Based on SBSI-YOLO11[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 80 -91 .
[8] YI Jianbing, HU Yayi, CAO Feng, LI Jun, PENG Xin, CHEN Xin. Design of Lightweight Pulmonary Nodules Detection Network on CT Images with Dynamic Channel Pruning[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 92 -106 .
[9] LU Mengxiao,ZHANG Yangchun,ZHANG Xiaofeng. Controlling Value Estimation Biasin Successor Features by Distributional Reinforcement Learning[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 107 -119 .
[10] JIANG Yunlu, LU Huijie, HUANG Xiaowen. Application Research of Penalized Weighted Composite Quantile Regression Method in Fixed Effects Panel Data[J]. Journal of Guangxi Normal University(Natural Science Edition), 2025, 43(6): 120 -127 .
Copyright © Journal of Guangxi Normal University(Natural Science Edition), All Rights Reserved.
Tel: 0773-5857325　E-mail: gxsdzkb@mailbox.gxnu.edu.cn
Powered by Beijing Magtech Co. Ltd